The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.
 
Mario E. Lacouture
Stock and Other Ownership Interests - Oncoderm (I)
Honoraria - Apricity Health; AstraZeneca; Deciphera; Incyte; Innovaderm; Janssen; L'Oreal; La Roche-Posay; Lutris; MJH Associates; Nanology; Novartis; Novocure; OnQuality Pharmaceuticals; RBC consultants; Relay Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Tyra Biosciences
Consulting or Advisory Role - Apricity Health; AstraZeneca; Deciphera; Genentech; Incyte; Innovaderm; Janssen Research & Development; La Roche-Posay; Lutris; Novartis; Novocure; OnQuality Pharmaceuticals; Relay Therapeutics; Roche; Roche; Seagen; Tyra Biosciences
Research Funding - AstraZeneca/MedImmune (Inst); Columbia University (Inst); Lutris; National Jewish Health (Inst); Novartis (Inst); Novocure; Paxman; US Biotest
Other Relationship - Oncoderm (I)
(OPTIONAL) Uncompensated Relationships - Oncoderm
 
Alexander Pan
No Relationships to Disclose
 
George Dranitsaris
No Relationships to Disclose
 
Ucalene Harris
No Relationships to Disclose
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Inivata; Lilly; Novartis; Paige.ai; Sanofi
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Totus Medicines
 
Chau T. Dang
Consulting or Advisory Role - Daichii Sankyo; eviCore healthcare; Gilead Sciences; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - Genentech/Roche (Inst); Puma Biotechnology (Inst)
 
Devika Gajria
Honoraria - Gerson Lehrman Group
Consulting or Advisory Role - Gerson Lehrman Group
 
Allison Gordon
No Relationships to Disclose
 
Neil M. Iyengar
Consulting or Advisory Role - Novartis; Seagen
Research Funding - American Cancer Society (Inst); Breast Cancer Research Foundation (Inst); Conquer Cancer Foundation (Inst); National Cancer Institute (Inst); Novartis (Inst)
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst)
Other Relationship - Clinical Care Options; Clinical Education Alliance; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Daiichi Sankyo; Epic Sciences; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Pedram Razavi
Honoraria - Daiichi Sankyo/Lilly; Epic Sciences; Guardant Health; Inivata; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Foundation Medicine; Guardant Health; Inivata; Natera; Novartis; Tempus
Research Funding - Archer (Inst); AstraZeneca (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Illumina (Inst); Novartis (Inst); Tempus (Inst)
 
Ezra Rosen
No Relationships to Disclose
 
Serena Tsan-Lai Wong
No Relationships to Disclose
 
Manu Jain
No Relationships to Disclose
 
Andrea Moy
No Relationships to Disclose
 
Alina Markova
Consulting or Advisory Role - Alira Health; Janssen
Research Funding - Amryt Pharma (Inst); Incyte (Inst)